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Background: Limited data describe patient-reported outcomes (PROs) of localised oesophageal cancer treated with definitive
chemoradiotherapy(CRT). The phase 2/3 SCOPE-1 trial assessed the effectiveness of CRT±cetuximab. The trial for the first time
provided an opportunity to describe PROs from a multi-centre group of patients treated with CRT that are presented here.
Methods: Patients undergoing CRT±cetuximab within the SCOPE-1 trial (258 patients from 36 UK centres) completed generic-,
disease- and treatment-specific health-related quality of life (HRQL) questionnaires (EORTC QLQ-C30, QLQ-OES18, Dermatology
Life-Quality Index (DLQI)) at baseline and at 7, 13, 24, 52 and 104 weeks. Mean EORTC functional scale scores (415 point change
significant), DLQI scores (44 point change significant) and proportions of patients (415% significant) with ‘minimal’ or ‘severe’
symptoms are presented.
Results: Questionnaire response rates were good. At baseline, EORTC functional scores were high (475%) and few symptoms
were reported except for severe problems with fatigue, insomnia and eating-related symptoms (e.g., appetite loss, dysphagia, dry
mouth) in both groups(415%). Functional aspects of health deteriorated and symptoms increased with treatment and by week 13
global quality of life, physical, role and social function significantly deteriorated and more problems with fatigue, dyspnoea,
appetite loss and trouble with taste were reported. Recovery occurred by 6 months (except severe fatigue and insomnia in415%
of patients) and maintained at follow-up with no differences between groups.
Conclusions: CRT for localised oesophageal cancer has a significant detrimental impact on many aspects of HRQL; however, recovery
is achieved by 6 months and maintained with the exception of persisting problems with severe fatigue and insomnia. The data suggest
that the HRQL recovery after definitive CRT is quicker, and there is little lasting deficit compared with treatment including surgery.
These data need to be compared with HRQL data from studies evaluating treatments including surgery for oesophageal cancer.
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Oesophageal cancer remains difficult to cure with overall 5-year
survival rates o10%. (Jemal et al, 2011) Radical treatment, often
including surgery, is undertaken in 20–30% of patients, although
o25% of patients survive 5 years (MRC Oesophageal Cancer
Working Party, 2002; Ychou et al, 2011). Oesophagectomy is
associated with significant in-hospital risk, with a mortality of
2–5%, major morbidity in 10–20% and a detrimental impact on
health-related quality of life (HRQL) (Jacobs et al, 2013). The
addition of neo-adjuvant chemotherapy or chemoradiotherapy
(CRT) before surgery can improve long-term survival,
(Ronellenfitsch et al, 2013a, b), but it is associated with additional
postoperative morbidity and deterioration of HRQL during
treatment (Derogar et al, 2012; Jacobs et al, 2014).
Radical non-surgical treatment with definitive radiotherapy may
also be used, but evidence shows that concurrent CRT is more
effective than radiotherapy alone (Wong and Malthaner, 2006;
Kranzfelder et al, 2011). Five-year survival rates after definitive CRT
are similar to those achieved by surgery although sufficiently robust
studies comparing these two approaches are lacking (Malthaner et al,
2006; Wong and Malthaner, 2006; Kranzfelder et al, 2011;
Ronellenfitsch et al, 2013b). Evaluation of radical treatment for
oesophageal cancer typically includes measures of long-term survival,
treatment toxicity and surgical morbidity. In addition, there is an
imperative to describe the patient perspective with measures of HRQL
that assess functions and symptoms directly reported by those
individuals receiving treatment (Food and Drug Administration,
2009). Studies using generic-, disease- and treatment-specific
measures can provide a comprehensive assessment of the effects of
therapy on patient experience, and these data contribute to clinical
decision making and support informed consent.
Patient-reported outcome (PRO) data are particularly relevant
during and after treatment for oesophageal malignancy because of
the overall poor outcomes observed, even if patients receive radical
interventions. A number of studies have described the effect of
surgical treatments with or without neoadjuvant therapy on HRQL
(Blazeby et al, 2005; Parameswaran et al, 2008; Jacobs et al, 2012).
However, the impact of definitive CRT on HRQL is less well
described, and the available data are mainly from small, single-
centre studies (Avery et al, 2007; Bedenne et al, 2007; Yamashita
et al, 2009a). A recent randomised trial of CRT with or without
cetuximab (the SCOPE-1 trial, a Cancer Research UK funded trial
co-ordinated by the Wales Cancer Trial Unit in Cardiff University)
included a comprehensive assessment of HRQL and recruited 258
patients from 36 UK centres. No differences in the prespecified
HRQL domains were observed between the treatment groups and
the addition of cetuximab to CRT could not be recommended for
localised oesophageal cancer as there were increased numbers of
treatment failures in the CRT plus cetuximab group (Crosby et al,
2013). However, the detailed trajectory of generic-, disease- and
treatment-specific PROs were not described, and this report aims
to provide the largest comprehensive description of the impact of
definitive CRT treatment for localised oesophageal cancer on
PROs, including HRQL, functions and symptoms.
MATERIALS AND METHODS
Participants and methods. SCOPE-1 was a multi-centre, open-
label, randomised, parallel, two-arm, phase 2/3 trial, which did not
continue past the phase 2 component. Full details of inclusion and
exclusion criteria, recruitment and randomisation procedures and
therapy have been reported (Hurt et al, 2011; Crosby et al, 2013).
Briefly, patients with non-metastatic, histologically confirmed
carcinoma of the oesophagus (adenocarcinoma, squamous cell or
undifferentiated carcinoma) or gastro-oesophageal junction were
eligible. Patients had disease either unsuitable for surgical therapy
or individual patients had elected not to undergo surgery. All had
full discussion at a specialist upper gastro-intestinal cancer multi-
disciplinary team meeting. Patients were randomised 1:1 to CRT
with cetuximab or CRT alone by stratified minimisation with a
random element (80:20). Stratification was by recruiting hospital,
primary reason for not having surgery, tumour histology and stage.
All participants signed an informed consent. Multi-centre ethical
approval was obtained, and the protocol was approved by the UK
Medicines and Healthcare products Regulatory Agency.
Treatment protocol. CRT consisted of cisplatin 60mgm 2 (day 1)
and capecitabine 625mgm 2 twice daily (days 1–21) for four
cycles; cycles three and four were given concurrently with
radiotherapy. The total dose of radiotherapy was 50Gy in 25
fractions over 5 weeks (Monday–Friday) using 3-D conformal
planning. The dose of Cetuximab was 400mgm 2 on day 1
followed by 250mgm 2 weekly given during induction che-
motherapy as well as in the concurrent CRT phase. No adjuvant
treatment was planned following CRT.
Study outcomes. The primary end point of the phase 2
component of the study was proportion of patients who were
treatment failure-free at week 24; for the phase 3 component,
overall survival was the primary end point. Secondary end points
included progression-free survival, PROs (see below), health
economics, toxicity (as per CTCAE version 3.0), treatment
compliance and feasibility of recruitment.
Patient-reported outcomes. PROs were secondary end points in
this trial and were assessed using the EORTC core questionnaire, the
EORTC QLQ-C30 (version 3.0) (Aaronson et al, 1993), the disease
specific module for oesophageal cancer, the QLQ-OES18 (Blazeby
et al, 2003) and the treatment-specific validated Dermatology Life-
Quality Index (DLQI) (Finlay and Khan, 1994) in paper format. The
QLQ-C30 is a widely used and validated generic cancer ques-
tionnaire that assesses global quality of life, functional domains
(physical, emotional, social, role and cognitive) and symptoms
(fatigue, nausea and vomiting, pain, dyspnoea, insomnia, appetite
loss, constipation, diarrhoea, financial difficulty) that commonly
occur in patients with cancer. The QLQ-OES18 has four symptom
scales assessing dysphagia, eating restrictions, reflux and pain and
six single symptom items (trouble with saliva, choking, dry mouth,
taste, cough and speech). All functional QLQ-C30 and QLQ-OES18
responses were linearly transformed to scores from 0 to 100 (Fayers
et al, 2002). In the functional scales, high scores represent better
quality of life (better function). Responses to the symptom items and
scales in the EORTC questionnaires were shown to be skewed, and
to appropriately summarise these data, the responses were
categorised as either ‘minimal’ or ‘severe’. Responses of ‘not at all’
and ‘a little’ being categorised as ‘minimal’ and responses ‘quite a bit’
or ‘very much’ categorised as ‘severe’ (Parameswaran et al, 2010;
Rees et al, 2012).
The DLQI is a 10-item instrument that produces scores from 0
to 30 where the higher the score, the greater the impairment. Data
from the DQLI were analysed according to the developer’s
instructions (Finlay and Khan, 1994). Nine of the 10 questions
are scored on a four-point scale from zero to three and question
number 7 has a dichotomous response scored zero or three. If a
single question was not completed then this question was scored
zero; if more than one question was incomplete the questionnaire
was considered void. If more than one response was marked, then
the highest score was used in the summation. If a single marked
response covered two options, the lower score was used for the
overall summation.
Assessment points were chosen to describe PRO changes across
time from before randomisation (baseline – 2 weeks before
treatment start), at anticipated low points during therapy (7 weeks
and 13 weeks) and at intervals that captured PROs during recovery
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(26 weeks) and in follow-up (52 weeks and 106 weeks). Time
windows of ±3 weeks were applied for each assessment, which
coincided with attendance for clinical follow-up visits. Question-
naires were checked at clinic visits to minimise missing items and
assessments.
Data analyses. The primary trial was designed as a phase 2/3 with
the independent data monitoring committee reviewing phase 2
data after 180 patients had a primary outcome (Crosby et al, 2013).
The primary outcome in phase 2 was the proportion of patients
who were treatment failure-free at 24 weeks. This was defined
using the number who died or progressed before 24 weeks with
those with a valid 24-week assessment as the denominator. All
randomly assigned patients who met the eligibility criteria in the
analysis of their allocated group were included. In the primary
paper, the prespecified PROs were compared by treatment group.
In this study, the full PRO data are described.
For EORTC functional scales, the mean scores and 95%
confidence intervals (CIs) at each time point are presented and a
change of X15 points was considered clinically significant (Osoba
et al, 1998). For EORTC symptoms scales, proportions of patients
with severe/minimal symptoms were calculated with 95% Wilson
CIs for each item at each time point owing to the skewed nature of
the raw data, if proportions changed byX15% this was considered
clinically significant (Parameswaran et al, 2010; Rees et al, 2012).
To maximise the available data, all fully completed question-
naires were included as were questionnaires if half or more of the
items within a scale were completed (Fayers et al, 2002). Missing
data were imputed according to EORTC guidance where it is
assumed that the missing items have values equal to the average of
those items which were present for that respondent. Where data
were missing from more than half the items within any scale, these
scales were excluded from the analyses (Fayers et al, 2002). When a
complete questionnaire was missing, the reason for the missing
questionnaire was ascertained and categorised as (i) administrative
failure, (ii) refusal, (iii) ill health, or (iv) due to an unknown or
other reason.
For the DLQI, each score was summed to a final total out of 30
and was interpreted using the developer’s validated recommenda-
tions, where a higher score reflects a greater impairment to quality
of life, 0–1¼ no effect, 2–5¼ small effect, 6–10¼moderate effect,
11–20¼ large effect, and 21–30¼ extremely large effect. A change
in DQLI score of X4 points is considered clinically significant
(Basra et al, 2008). In addition, an exploratory analysis of the scales
that constitute the overall DLQI measure under the headings
symptoms and feelings, daily activities, leisure, work and school,
personal relationships and treatment was undertaken with each
heading reflecting a single item or two items forming a scale of the
DLQI. Mean scores and 95% CIs were calculated and reported for
the overall DLQI result and the scales. All analyses were
undertaken and graphs produced using the STATA statistical
software version 13.0 (Stata, College Station, TX, USA).
Trial management. The independent data monitoring committee
met and reviewed the data five times at regular intervals
during recruitment and, when reviewing the phase 2 results,
made the decision to not recommend continuation of recruitment
into phase 3 on 22 February 2012. All recruited patients
were followed up to 24 weeks and PRO data were collected up
to 104 weeks. This study is registered at ISRCTN, number
47718479. The protocol is published (Hurt et al, 2011) and a copy
of full protocol can be accessed at: http://clinicaltrials.gov/ct2/
show/NCT00509561?term=SCOPE1&rank=2.
Role of funding source. The trial was developed on behalf of the
NCRI Upper GI Clinical Studies Group and Cancer Research UK’s
Clinical Trials Awards and Advisory Committee (CTAAC)
approved the trial design. Merck provided the cetuximab and
540 Patients assessed for eligibility
258 Randomly assigned
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129 Chemoradiotherapy
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Figure 1. CONSORT PRO flow diagram.
Table 1. Questionnaire compliance and reasons for missing data by treatment group
Baseline 7 weeks 13 weeks 26 weeks 52 weeks 104 weeks
CRT CRTþC CRT CRTþC CRT CRTþC CRT CRTþC CRT CRTþC CRT CRTþC
Eligible 129 129 127 114 109 125 108 113 100 87 79 56
Died 0 0 1 0 6 2 15 9 20 33 36 61
Withdrew 0 0 1 15 14 2 6 7 9 9 10 7
Questionnaire not due 0 0 0 0 0 0 0 0 0 0 4 5
Returned (%) 122 (94.6) 124 (96.0) 104 (81.9) 93 (81.6) 100 (91.7) 87 (79.8) 89 (82.4) 86 (76.1) 74 (74.0) 65 74.7) 50 (63.3) 35 (62.5)
Administration 0 0 8 7 2 8 12 10 10 10 10 8
Patient declined 0 0 3 0 1 4 3 1 2 1 2 2
Patient too unwell 0 0 0 2 4 4 2 2 3 4 1 2
Other 0 0 3 5 2 8 2 6 11 2 2 4
No reason known 7 5 9 7 0 14 0 8 0 5 14 5
Abbreviations: CRT¼ chemoradiotherapy; CRTþC¼ chemoradiotherapy plus cetuximab.
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had no role in study design, data collection, analysis or
interpretation or writing of this report. JR, JB and CH had full
access to all the data and, along with the chief investigator (TC),
had the final responsibility to submit for publication.
RESULTS
Between February 2008 and 2012, 258 patients (129 assigned to
each treatment group) from 36 UK centres were recruited, and as
described above, the trial was stopped at the end of the phase 2
based on futility. Full details of the clinical outcomes are presented
elsewhere (Crosby et al, 2013).
Questionnaire compliance and missing data. Questionnaire
compliance was good throughout the study, initially being 122
out of 129 (94.6%) of those receiving CRT and 124 out of 129
(96.0%) of those receiving CRT plus cetuximab at baseline. Rates
remained high and only reduced to 62.9% by the 24-month
assessment in both groups (Figure 1). Details and reasons for
missing questionnaires are in Table 1.
PROs prior to treatment. Mean baseline EORTC functional and
global quality of life scores prior to treatment were 465 in both
groups (Supplementary Table S1, Figures 2A–D). Figures for global
quality of life, physical, role and emotional function are shown, and
figures for social and cognitive function are shown in
Supplementary Figures S1a and b, and similar patterns were
observed. Baseline symptoms were minimal in most patients except
that 415% of patients in both groups reported severe problems
with fatigue, appetite loss, eating restrictions, dry mouth, trouble
with saliva and dysphagia (Supplementary Table S1, Figures 3A–D).
Figures for other EORTC symptom scores are not shown, but
similar patterns were observed (Supplementary Table S2). Baseline
DLQI scores were very low (few symptoms) with worst problems
noted for ability to work (Figure 4; Supplementary Table S3).
PROs during treatment. Most functional PROs deteriorated in
both groups during treatment, and by 13 weeks reductions in mean
scores of 415 points were observed in both groups for global
quality of life and physical, social and role function (Figures 2A–C).
Similarly, patients reported more symptoms (Figures 2A–C).
Proportions of patients with severe symptoms were increased in
both groups by 415% for fatigue, dyspnoea, appetite loss and
trouble with taste at 13 weeks; increases were similar in both
groups. Patients receiving cetuximab reported worse overall DLQI
scores than those receiving CRT alone, although these did not
reach clinical significance (mean score changes o4 points)
(Figure 4; Supplementary Table S3).
PROs during follow-up. Most PROs recovered to baseline levels
by 26 weeks (Supplementary Tables S1 and S2, Figures 2A–D and
Figures 3A–D). Severe symptoms experienced during treatment all
resolved and were maintained in follow-up except for on-going
problems with fatigue and insomnia (reported by 415% of
patients during follow-up). There were no clinically significant
changes in mean function scores between baseline and the
104-week assessment (functional scores were similar to the start
of treatment) and symptoms showed a similar pattern, although
clinically significant improvements (415% reduction) in appetite
loss and eating restrictions were reported at the final assessment
time. Scores did not differ between treatment groups
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(Supplementary Tables S1 and S2, Figures 5A–C and Figures 6A–
C). Throughout follow-up, DLQI scores were low and stable (i.e.,
few problems) (Figure 4; Supplementary Table S3).
DISCUSSION
Although the SCOPE-1 trial was closed by the independent data
monitoring committee because of futility, it showed that CRT with
or without cetuximab is associated with 2-year survival similar to
that reported by surgical randomised trials and large
series (Macdonald et al, 2001; Cunningham et al, 2006;
Gebski et al, 2007; Tepper et al, 2008). An important aspect of
the SCOPE-1 trial was its detailed assessment of PRO in a
multi-centre study setting in patients with localised oesophageal
cancer undergoing definitive CRT. Generic-, disease- and
treatment-specific PROs were completed, and good questionnaire
response rates were obtained in both groups at baseline and
follow-up to 24 months. Results show a significant deterioration in
functional scores and increased symptoms during treatment
particularly at 13 weeks, which should direct clinicians to
particularly focus supportive care for patients at this time.
Recovery of most PROs was achieved by 6 months, and by 104
weeks scores were similar or better than before treatment.
These data, therefore, can be used in clinical decisionmaking to
inform patients of the PRO during and following definitive CRT,
and they suggest that recovery of PROs after CRT is better that that
reported after treatments including surgery (Reynolds et al, 2006;
Avery et al, 2007). This is an important and novel observation that
requires further evaluation.
Previous research examining PROs in non-surgical
radical treatment of oesophageal cancer has been limited to small,
single-centre studies (Avery et al, 2007; Ariga et al, 2009;
Jacobs et al, 2012). Although validated EORTC generic- and
disease-specific measures were often used, many did not
report baseline data or reasons for missing assessments.
Recently, the clinical results from multi-centre RCT examining two
CRT regimens has been reported. The study did assess PROs with
EORTC generic- and disease-specific measures, and PRO data will
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Figure 6. Waterfall plot showing (A) Mean change in PRO scores from
baseline to 104 weeks in patients receiving chemo-radiotherapy and
cetuximab. (B) Mean change in PRO scores from baseline to 104 weeks
in patients receiving CRT alone. (C) Mean change in HRQL outcomes
from baseline to 104 weeks. Positive values in the functional scales and
negative values for the symptom scale denote overall benefit from CRT
with cetuximab (CRTþCetuximab) compared with CRT alone.
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be reported separately (Conroy et al, 2014). The separate reporting
of clinical trial data and PROs may reduce the use of the PRO data
in decisionmaking, because clinicians may read the initial report in
a main stream journal but not be aware of the secondary
publication of the detailed PRO information. This issue has been
highlighted in the recent PRO CONSORT extension that
recommends that trial papers report both sets of data to enable
the use of the information in practice (Calvert et al, 2013).
Unlike definitive CRT, there has been extensive and in-depth
study of PRO after surgical treatment for localised oesophageal
cancer (Blazeby et al, 2000; Gillham et al, 2008; Yamashita et al,
2009b; Derogar et al, 2012; Jacobs et al, 2014). Generally studies
show a marked deterioration in PRO following surgery that
takes 6–9 months to recover, and patients who do not survive42
years do not recover their quality of life. Studies of long-term
survivors of surgery using EORTC measures show that persistent
problems with dyspnoea, reflux and physical function occur at 104
weeks and beyond, but no deficits with eating restrictions are
reported. Therefore, this current study that examines in detail
PRO after definitive CRT treatment provides new information
about PRO in long-term survivors of CRT that may be used in
clinical decisionmaking for patients who may be suitable
for a surgical or non-surgical radical approach for oesophageal
cancer. Randomised comparative analyses of PRO between CRT
and surgical treatments for oesophageal cancer are still
needed, although this type of study will be difficult to conduct
(Blazeby et al, 2014). This study has several limitations. Despite
efforts, questionnaire return rates in the later stages of the
study reduced to 62% in both groups. It is possible that non-
responders had different PRO profiles to responders, and there is
bias in the results. It also has limited long-term follow-up (to 104
weeks only), and 5-year survival and HRQL data following
definitive CRT are still needed. It is also possible that the
DLQI tool for assessing skin symptoms, which showed minimal
change in this study, may lack the sensitivity necessary to detect
skin problems related to the use of cetuximab. Finally, it is possible
that patients with squamous cell cancer may have different
responses to CRT compared with adenocarcinoma and this may
be apparent in the PRO scores. These analyses have not been
undertaken and could only be considered exploratory from this
data set. We also acknowledge that the inclusion criteria allowed a
heterogeneous population – patients with advanced inoperable
disease, those who were medically unfit for surgery as well as
patient who elected to have non-surgical treatment. These groups
may have had different HRQL profiles and these differences
have not been captured in this study. It should also be recognised
that clinical trial outcomes do not always reflect that achievable in
the community, for example, patients with severe dysphagia
may have undergone primary stenting and could have been
excluded from the trial. A final weakness is that the rates of
interventions for dysphagia during follow-up (the need for
dilatation) were not recorded. It is possible that the surviving
patients (who reported few problems with dysphagia and eating
restrictions) require several dilatations to maintain this – although
this is speculation alone.
In summary, this study has investigated PRO in localised
oesophageal cancer; this detailed analysis highlights significant new
findings not described in the initial clinical paper (Crosby et al,
2013) and demonstrates that there is a severe detrimental impact
on function and symptoms during treatment. These problems
resolve by 6 months and in survivors few symptoms are reported 2
years after treatment. The data suggest that the HRQL recovery
after definitive CRT is quicker and there is little lasting deficit
compared with treatment including surgery. This underlines the
need for a well-designed and conducted RCT comparing definitive
CRT with treatment including surgery for localised oesophageal
cancer (Blazeby et al, 2014).
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